Identification of Biomarkers for Preeclampsia Based on Metabolomics

Mengxin Yao1, Yue Xiao1, Zhuoqiao Yang1

  • 1Department of Epidemiology and Health Statistics, Medical College of Soochow University, Suzhou, People's Republic of China.

Clinical Epidemiology
|March 28, 2022
PubMed

Insights

This review identifies key metabolic biomarkers and pathways linked to preeclampsia (PE). These findings offer potential for early PE diagnosis and a deeper understanding of its complex pathogenesis.

Area of Science:

  • Metabolomics
  • Biochemistry
  • Obstetrics

Background:

  • Preeclampsia (PE) poses significant global risks to maternal and neonatal health.
  • The underlying causes of PE remain largely unknown, hindering early diagnosis.
  • There is a critical need for reliable early diagnostic methods and a better understanding of PE's metabolic mechanisms.

Purpose of the Study:

  • To systematically review and summarize potential metabolic biomarkers associated with PE.
  • To identify key metabolic pathways implicated in the pathogenesis of PE.
  • To explore the utility of these biomarkers and pathways for risk prediction, clinical diagnosis, and understanding PE mechanisms.

Main Methods:

  • A systematic review of human metabolomics studies on PE was conducted.
  • Literature search performed across PubMed, Google Scholar, and Web of Science (Jan 2000 - Nov 2021).
  • Metabolites and biomarkers were systematically examined, and pathway analysis was performed using MetaboAnalyst 5.0.

Main Results:

  • Forty-one studies were included, identifying consistent metabolites like creatinine, glycine, L-isoleucine, and glucose.
  • Key biomarkers with consistent trends included decanoylcarnitine, 3-hydroxyisovaleric acid, and octenoylcarnitine.
  • Identified pathways involved amino acid, carbohydrate, lipid metabolism, and translation, linked to renal dysfunction, insulin resistance, inflammation, and impaired nitric oxide production.

Conclusions:

  • Several metabolites and metabolic pathways are strongly associated with PE.
  • High-frequency differential metabolites show promise as early diagnostic biomarkers for PE.
  • Identified metabolic pathways may offer novel insights into the pathogenesis of PE.
Abstract